NASDAQ · Financial Statements

Cumberland Pharmaceuticals Inc. (CPIX) Revenue, Earnings & Financial Statements

$5.80 NASDAQ: CPIX Market Cap $86.90M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Cumberland Pharmaceuticals Inc. most recently reported annual revenue of $45.0M, a net loss of $3.0M. Revenue grew at an average annual rate of 4.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Cumberland Pharmaceuticals Inc.: Revenue rose from $33.0M in 2016 to $45.0M in 2025, a change of +36.4% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -4.3% to -6.3%, a shift of -1.9 percentage points; the most recent year shows a net loss of $3.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$33.0M$41.0M$41.0M$34.0M$37.0M$36.0M$42.0M$40.0M$38.0M$45.0M
Operating Expenses$34.0M$45.0M$48.0M$44.0M$44.0M$44.0M$48.0M$49.0M$44.0M$47.0M
Operating Profit−$1.0M−$4.0M−$7.0M−$9.0M−$6.0M−$8.0M−$6.0M−$10.0M−$6.0M−$3.0M
Operating Margin-4.3%-9.9%-18.1%-27.0%-17.0%-21.3%-13.6%-24.2%-17.0%-6.3%
Other Income$0$0$0$0$0$2.0M$0$3.0M$0$0
Interest$0$0$0$0$0$0$1.0M$1.0M$1.0M$0
Depreciation$2.0M$3.0M$3.0M$4.0M$5.0M$5.0M$5.0M$6.0M$6.0M$5.0M
Profit Before Tax−$1.0M−$4.0M−$7.0M−$9.0M−$7.0M−$6.0M−$6.0M−$6.0M−$6.0M−$3.0M
Tax rate (%)24.8%-107.7%-0.2%0.8%-0.8%-0.6%-1.2%-0.7%0.3%-1.4%
Net Profit−$1.0M−$8.0M−$7.0M−$4.0M−$3.0M−$4.0M−$6.0M−$6.0M−$6.0M−$3.0M
EPS−$0.06−$0.50−$0.45−$0.23−$0.22−$0.24−$0.38−$0.44−$0.46−$0.19

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$9.0M$8.0M$10.0M$9.0M$10.0M$12.0M$11.0M$8.0M$14.0M$9.0M$0$2.0M
Operating Expenses$16.0M$10.0M$11.0M$11.0M$12.0M$10.0M$12.0M$10.0M$15.0M$12.0M$3.0M$4.0M
Operating Profit−$6.0M−$2.0M−$1.0M−$2.0M−$2.0M$1.0M−$1.0M−$2.0M−$1.0M−$3.0M−$3.0M−$2.0M
Operating Margin-66.1%-22.0%-10.4%-18.6%-17.6%11.0%-6.9%-23.7%-10.0%-34.3%-1898.7%-89.8%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$6.0M−$2.0M−$1.0M−$2.0M−$2.0M$1.0M−$1.0M−$2.0M−$1.0M−$3.0M−$3.0M−$1.0M
Tax rate (%)-0.4%-0.6%-1.1%-0.8%2.9%0.5%-0.8%-0.3%-1.6%-0.1%-0.1%-0.3%
Net Profit−$6.0M−$2.0M−$1.0M−$2.0M−$2.0M$1.0M−$1.0M−$2.0M−$1.0M−$3.0M−$4.0M$78.0M
EPS−$0.44−$0.14−$0.08−$0.11−$0.14$0.08−$0.05−$0.13−$0.09−$0.22−$0.27$5.07

Over the 10 years reported for Cumberland Pharmaceuticals Inc., borrowings increased from $4.0M in 2016 to $10.0M in 2025, cash stood at $11.0M in the latest year, shareholders' equity was $52.0M, current assets covered current liabilities 1.00 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$93.0M$93.0M$113.0M$105.0M$96.0M$84.0M$93.0M$82.0M$76.0M$77.0M
Current Assets$66.0M$69.0M$75.0M$50.0M$50.0M$46.0M$46.0M$36.0M$36.0M$37.0M
Cash$35.0M$45.0M$28.0M$28.0M$25.0M$27.0M$20.0M$18.0M$18.0M$11.0M
Inventory$5.0M$7.0M$28.0M$9.0M$11.0M$8.0M$10.0M$5.0M$4.0M$6.0M
Receivables$7.0M$8.0M$8.0M$8.0M$12.0M$7.0M$13.0M$10.0M$12.0M$17.0M
Fixed Assets$0$1.0M$1.0M$4.0M$3.0M$1.0M$6.0M$7.0M$6.0M$9.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$16.0M$5.0M$8.0M$0$0$0$0$0$0$4.0M
Other Assets$0$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Total Liabilities$20.0M$29.0M$57.0M$53.0M$50.0M$42.0M$57.0M$53.0M$53.0M$52.0M
Current Liabilities$15.0M$18.0M$28.0M$24.0M$26.0M$19.0M$29.0M$28.0M$32.0M$37.0M
Borrowings$4.0M$10.0M$20.0M$21.0M$19.0M$16.0M$21.0M$18.0M$21.0M$10.0M
Other Liabilities$16.0M$20.0M$37.0M$32.0M$30.0M$26.0M$36.0M$34.0M$32.0M$42.0M
Equity$55.0M$52.0M$51.0M$50.0M$49.0M$48.0M$47.0M$47.0M$47.0M$52.0M
Reserves$73.0M$64.0M$56.0M$51.0M$47.0M$43.0M$36.0M$30.0M$23.0M$25.0M

For Cumberland Pharmaceuticals Inc., operating cash flow was positive in 8 of 10 reported years; free cash flow in the latest year was $5.0M; free cash flow was positive in 6 of 10 years; financing activities used $2.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$1.0M−$1.0M$3.0M$3.0M$5.0M$6.0M$8.0M$6.0M−$1.0M$5.0M
Investing Cash Flow−$5.0M$8.0M−$39.0M$2.0M−$4.0M−$1.0M−$16.0M−$1.0M$0−$5.0M
Financing Cash Flow−$4.0M−$4.0M−$3.0M−$4.0M−$4.0M−$4.0M−$3.0M−$4.0M−$2.0M−$2.0M
Net Cash Flow−$4.0M$11.0M−$17.0M$0−$3.0M$2.0M−$7.0M−$1.0M$0−$7.0M
Free Cash Flow−$2.0M−$2.0M−$1.0M$3.0M$3.0M$6.0M$6.0M$6.0M−$1.0M$5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-2.13
FCF Yield-1.18%
Quick Ratio3.04
Interest Coverage-47.02
Return 1Y293.66%
Return 3Y347.88%
Return 5Y193.32%

Cumberland Pharmaceuticals Inc. (CPIX) financials — frequently asked questions

What is Cumberland Pharmaceuticals Inc.'s annual revenue?

Cumberland Pharmaceuticals Inc. (CPIX) reported annual revenue of $45.0M in its most recent fiscal year.

What is Cumberland Pharmaceuticals Inc.'s net profit?

Cumberland Pharmaceuticals Inc. (CPIX) reported a net loss of $3.0M in its most recent fiscal year.

What is CPIX EV/EBITDA?

Cumberland Pharmaceuticals Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.13. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Drug Manufacturers - Specialty & Generic stocks

TEVA revenue $17.3BZTS revenue $9.5BVTRS revenue $14.3BELAN revenue $4.7BRDY revenue $353.5BALKS revenue $1.5BAMRX revenue $3.0BLNTH revenue $1.5BSUPN revenue $719.0MBHC revenue $10.3BAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
CPIX Overview CPIX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.